Plain-English translation of NCT05000294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications— and —to treat several types of cancer that have historically been difficult to treat with immunotherapy alone. The first medication helps wake up your immune system to fight cancer, while the second medication improves blood flow to the tumor, potentially making the immune system's attack more effective. Researchers hope this combination approach will help patients whose cancers haven't responded to standard treatments.
Many cancers, like pancreatic cancer, prostate cancer, and certain bile duct cancers, don't respond well to immunotherapy by itself because they have poor blood flow and can hide from the immune system. This medication combination is designed to address that problem by targeting both the immune system and the abnormal blood vessels that help tumors grow and hide.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications, likely as pills or infusions, on a regular schedule overseen by the research team. You would attend regular clinic visits for blood tests, imaging scans to monitor your cancer, and check-ins to make sure the treatment is working and to manage any side effects. The trial involves two phases—a smaller phase testing safety first, followed by a larger phase testing effectiveness—so your exact schedule may depend on which phase you join.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States